YM-60828, a novel factor Xa inhibitor: Separation of its antithrombotic effects from its prolongation of bleeding time

By Sato K.   Kawasaki T.   Taniuchi Y.   Hirayama F.   Koshio H.   Matsumoto Y.  

European Journal of Pharmacology, Vol. 339, Iss. 2, 1997-11 ,pp. : 141-146

Elsevier

Access to resources Recommend Favorite

Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time

By Sato K.   Kaku S.   Hirayama F.   Koshio H.   Matsumoto Y.   Kawasaki T.   Iizumi Y.  

European Journal of Pharmacology, Vol. 352, Iss. 1, 1998-07 ,pp. : 59-63

Elsevier

Access to resources Recommend Favorite

Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy

By Turpie Alexander GG  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 6, 2004-06 ,pp. : 1373-1384

Informa Healthcare

Access to resources Recommend Favorite

Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin

By Kadokura Takeshi   Groenendaal Dorien   Heeringa Marten   Mol Roelof   Verheggen Frank   Garcia-Hernandez Alberto   Onkels Hartmut  

European Journal of Drug Metabolism and Pharmacokinetics, Vol. 39, Iss. 1, 2014-03 ,pp. : 1-9

Springer Publishing Company

Access to resources Recommend Favorite

Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis

By Heran C.   Morgan S.   Kasiewski C.   Bostwick J.   Bentley R.   Klein S.   Chu V.   Brown K.   Colussi D.   Czekaj M.   Perrone M.   Leadley R.  

European Journal of Pharmacology, Vol. 389, Iss. 2, 2000-02 ,pp. : 201-207

Elsevier

Access to resources Recommend Favorite